Abstract
Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have